financier worldwide

Glaucus Research released an explosive report exposing alleged fraudulent transactions on the part of China Medical Technologies (NASDAQ: CMED). Compelling evidence suggests that CMED deliberately overpaid—to the tune of $20-23 million—for a company which its own Chairman was a stakeholder. The...